Difference between revisions of "Team:Chalmers-Gothenburg/HP/Silver"
| (21 intermediate revisions by the same user not shown) | |||
| Line 24: | Line 24: | ||
body { | body { | ||
background-color: #e6e6e6; | background-color: #e6e6e6; | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
font-family:'Lato', sans-serif; | font-family:'Lato', sans-serif; | ||
} | } | ||
| Line 208: | Line 203: | ||
top: 0; | top: 0; | ||
width: 100%; | width: 100%; | ||
| − | min-width: | + | min-width: 1440px; |
z-index:9999; | z-index:9999; | ||
-webkit-touch-callout: none; | -webkit-touch-callout: none; | ||
| Line 434: | Line 429: | ||
width: cover; | width: cover; | ||
| + | min-width:1440px; | ||
text-align: center; | text-align: center; | ||
margin: auto; | margin: auto; | ||
| Line 439: | Line 435: | ||
background:#e6e6e6; | background:#e6e6e6; | ||
| − | |||
| − | |||
| − | |||
| − | |||
} | } | ||
| Line 483: | Line 475: | ||
border-style: none none dashed dashed; | border-style: none none dashed dashed; | ||
border-width:5px; | border-width:5px; | ||
| − | border-color:# | + | border-color:#7e1002; |
padding-left:50px; | padding-left:50px; | ||
padding-right:50px; | padding-right:50px; | ||
| Line 495: | Line 487: | ||
border-style: none none dashed dashed; | border-style: none none dashed dashed; | ||
border-width:5px; | border-width:5px; | ||
| − | border-color:# | + | border-color:#7e1002; |
padding:50px; | padding:50px; | ||
} | } | ||
| Line 503: | Line 495: | ||
border-style: none dashed dashed none; | border-style: none dashed dashed none; | ||
border-width:5px; | border-width:5px; | ||
| − | border-color:# | + | border-color:#7e1002; |
padding:50px; | padding:50px; | ||
} | } | ||
| Line 511: | Line 503: | ||
border-style: none dashed none none; | border-style: none dashed none none; | ||
border-width:5px; | border-width:5px; | ||
| − | border-color:# | + | border-color:#7e1002; |
padding:50px; | padding:50px; | ||
} | } | ||
| Line 519: | Line 511: | ||
border-style: none none none dashed; | border-style: none none none dashed; | ||
border-width:5px; | border-width:5px; | ||
| − | border-color:# | + | border-color:#7e1002; |
padding:50px; | padding:50px; | ||
} | } | ||
| − | |||
| Line 554: | Line 545: | ||
text-align: left; | text-align: left; | ||
text-decoration: none; | text-decoration: none; | ||
| − | background: # | + | background: #f2f2f2; |
font-size:12pt !important; | font-size:12pt !important; | ||
} | } | ||
| Line 677: | Line 668: | ||
} | } | ||
| − | + | .header_test { | |
| − | . | + | background-position: top; |
| − | + | background-attachment: fixed; | |
| − | + | background-repeat: no-repeat; | |
| − | + | -webkit-background-size: cover; | |
| − | + | -moz-background-size: cover; | |
| − | + | -o-background-size: cover; | |
| − | + | background-size: cover; | |
| − | + | padding-top: 100vh; | |
| − | + | background-image: url("https://static.igem.org/mediawiki/2017/c/c8/T--Chalmers-Gothenburg--HP_HumanPractices.jpg"); | |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | /*A lot of code for the line between the header and the body */ | |
| − | + | border-bottom: 3px solid transparent; | |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
-moz-border-image: -moz-linear-gradient(left, #000000 0%, #404040, #000000 100%); /*(left, #016243 0%, #b5deca, #016243 100%);*/ | -moz-border-image: -moz-linear-gradient(left, #000000 0%, #404040, #000000 100%); /*(left, #016243 0%, #b5deca, #016243 100%);*/ | ||
-webkit-border-image: -webkit-linear-gradient(left, #000000 0%, #404040, #000000 100%); /*(left, #016243 0%, #b5deca, #016243 100%)*/ | -webkit-border-image: -webkit-linear-gradient(left, #000000 0%, #404040, #000000 100%); /*(left, #016243 0%, #b5deca, #016243 100%)*/ | ||
| Line 729: | Line 694: | ||
} | } | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | + | /* Banner: name of the page */ | |
| − | + | #banner { | |
| − | + | height: 100%; | |
| − | + | position: relative; | |
| − | + | bottom: 50px; | |
| − | + | float: left; | |
| − | + | width: 100%; | |
| − | + | font-size: 80pt; /*35pt*/ | |
| − | + | font-family:"Lato", cursive; | |
| − | + | color:#c91a03 ; | |
| − | + | line-height: 65pt; | |
| − | + | text-shadow: 5px 5px #000000; | |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
} | } | ||
| − | + | #banner h3 { | |
| − | + | display: block; | |
| − | + | position: absolute; | |
| − | + | bottom: 50px; | |
| − | + | left: 200px; | |
| − | + | font-size: 80pt; /*35pt*/ | |
| − | + | font-family:"Lato", cursive; | |
| − | + | color:#c91a03 ; | |
| − | + | line-height: 65pt; | |
| − | + | text-shadow: 5px 5px #000000; | |
| − | + | /*border-style:dashed;*/ | |
| − | + | padding: 20px 20px 20px 20px; | |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
} | } | ||
| − | + | #banner h4 { | |
| − | + | display: block; | |
| − | + | position: absolute; | |
| − | + | bottom: -40px; | |
| − | + | left: 200px; | |
| − | + | font-size: 40pt; /*35pt*/ | |
| − | + | font-family:"Lato", cursive; | |
| − | + | color:#c91a03 ; | |
| − | + | line-height: 65pt; | |
| − | + | text-shadow: 3px 3px #000000; | |
| − | + | /*border-style:dashed;*/ | |
| − | + | padding: 20px 20px 20px 20px; | |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
} | } | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
.header-text { | .header-text { | ||
background-color: transparent; | background-color: transparent; | ||
| Line 1,089: | Line 817: | ||
h2 { | h2 { | ||
text-align:left; | text-align:left; | ||
| + | font-size:18pt; | ||
} | } | ||
| Line 1,181: | Line 910: | ||
} | } | ||
| + | .figure-caption { | ||
| + | display: table-caption; | ||
| + | caption-side: bottom; | ||
| + | } | ||
| + | |||
| + | .table-caption { | ||
| + | display: table-caption; | ||
| + | caption-side: top; | ||
| + | color: black; | ||
| + | font-size: 11pt; | ||
| + | text-align: justify; | ||
| + | padding-left: 0px; | ||
| + | padding-right:0px; | ||
| + | margin-left:0px; | ||
| + | margin-right:0px; | ||
| + | } | ||
| + | |||
| + | th { | ||
| + | text-align: center; | ||
| + | } | ||
| + | |||
| + | figure { | ||
| + | display:table; | ||
| + | text-align:center; | ||
| + | margin: auto; | ||
| + | margin-bottom: 25px; | ||
| + | margin-top: 25px; | ||
| + | } | ||
| + | |||
| + | /*---Reference List---*/ | ||
| + | |||
| + | .reference_list { | ||
| + | text-align: left; | ||
| + | font-size:10pt; !important | ||
| + | } | ||
| + | |||
| + | .reference_list ul { | ||
| + | list-style-type: none; | ||
| + | list-style-image: none; | ||
| + | } | ||
| + | |||
| + | .reference_list li { | ||
| + | padding-bottom: 10px; | ||
| + | } | ||
/*--------------Links in text and lists are red when hovered------------------*/ | /*--------------Links in text and lists are red when hovered------------------*/ | ||
| Line 1,289: | Line 1,062: | ||
font-weight: 500; | font-weight: 500; | ||
} | } | ||
| + | |||
| Line 1,539: | Line 1,313: | ||
<body><div class="HP"> | <body><div class="HP"> | ||
| − | <div id="header_navbar_wrapper"> <!----------------------------- | + | <div id="header_navbar_wrapper"> <!----------------------------- header_navbar START --------------------------> |
<div id="header-nav-anchor"><!--Anchor for stickying the header navbar--> | <div id="header-nav-anchor"><!--Anchor for stickying the header navbar--> | ||
<nav><!--Used to apply a sticky class, so that the position can be changed to fixed--> | <nav><!--Used to apply a sticky class, so that the position can be changed to fixed--> | ||
<ul class="header_navbar_ul"> | <ul class="header_navbar_ul"> | ||
| − | <li id="header_navbar_home"><a href="https://2017.igem.org/Team:Chalmers-Gothenburg" id="home_link"> Home | + | <li id="header_navbar_home"><a href="https://2017.igem.org/Team:Chalmers-Gothenburg" id="home_link"> Home </a></li> |
<li class="dropdown"> | <li class="dropdown"> | ||
| Line 1,568: | Line 1,342: | ||
<a href="https://2017.igem.org/Team:Chalmers-Gothenburg/Project/constructs">Constructs</a> | <a href="https://2017.igem.org/Team:Chalmers-Gothenburg/Project/constructs">Constructs</a> | ||
<hr> | <hr> | ||
| − | <a href="https://2017.igem.org/Team:Chalmers-Gothenburg/Model">Mathematical | + | <a href="https://2017.igem.org/Team:Chalmers-Gothenburg/Model">Mathematical modeling</a> |
</div> | </div> | ||
</li> | </li> | ||
| Line 1,577: | Line 1,351: | ||
<a href="https://2017.igem.org/Team:Chalmers-Gothenburg/HP/Silver">Human practices</a> | <a href="https://2017.igem.org/Team:Chalmers-Gothenburg/HP/Silver">Human practices</a> | ||
<hr> | <hr> | ||
| − | <a href="https://2017.igem.org/Team:Chalmers-Gothenburg/HP/Gold_Integrated">Integrated | + | <a href="https://2017.igem.org/Team:Chalmers-Gothenburg/HP/Gold_Integrated">Integrated human practices</a> |
</div> | </div> | ||
</li> | </li> | ||
| Line 1,586: | Line 1,360: | ||
<a href="https://2017.igem.org/Team:Chalmers-Gothenburg/Results">Project results</a> | <a href="https://2017.igem.org/Team:Chalmers-Gothenburg/Results">Project results</a> | ||
<hr> | <hr> | ||
| − | <a href="https://2017.igem.org/Team:Chalmers-Gothenburg/Parts"> | + | <a href="https://2017.igem.org/Team:Chalmers-Gothenburg/Parts">Biobricks</a> |
<hr> | <hr> | ||
<a href="https://2017.igem.org/Team:Chalmers-Gothenburg/InterLab">Interlab study</a> | <a href="https://2017.igem.org/Team:Chalmers-Gothenburg/InterLab">Interlab study</a> | ||
<hr> | <hr> | ||
| − | <a href="https://2017.igem.org/Team:Chalmers-Gothenburg/Achievements/medal"> | + | <a href="https://2017.igem.org/Team:Chalmers-Gothenburg/Achievements/medal">Accomplishments</a> |
</div> | </div> | ||
</li> | </li> | ||
| Line 1,606: | Line 1,380: | ||
<!--facebook, instagram and twitter icon--> | <!--facebook, instagram and twitter icon--> | ||
| − | <li id="header_navbar_home"><a href="https://sv-se.facebook.com/chalmersigem/" id="fb"><i class="fa fa-facebook-square" style="font-size:24px"></i> </a></li> | + | <li id="header_navbar_home"><a href="https://sv-se.facebook.com/chalmersigem/" id="fb" target="_blank"><i class="fa fa-facebook-square" style="font-size:24px"></i> </a></li> |
| − | <li id="header_navbar_home"><a href="https://www.instagram.com/chalmersigem/" id="instagram"><i class="fa fa-instagram" style="font-size:24px"></i> </a></li> | + | <li id="header_navbar_home"><a href="https://www.instagram.com/chalmersigem/" id="instagram" target="_blank"><i class="fa fa-instagram" style="font-size:24px"></i> </a></li> |
| − | <li id="header_navbar_home"><a href="https://twitter.com/igemchalmers" id="twitter"><i class="fa fa-twitter" style="font-size:24px"></i> </a></li> | + | <li id="header_navbar_home"><a href="https://twitter.com/igemchalmers" id="twitter" target="_blank"><i class="fa fa-twitter" style="font-size:24px"></i> </a></li> |
| Line 1,621: | Line 1,395: | ||
<div class="wrap"> <!--To limit the width of the site--> | <div class="wrap"> <!--To limit the width of the site--> | ||
| − | + | <div class="header_test"> | |
| − | <div class=" | + | <!-- Banner --> |
| − | + | <div id="banner"> | |
| − | + | <h3>Human practices</h3> | |
| − | + | </div> | |
| + | </div> | ||
<!--This is the side navigation bar--> | <!--This is the side navigation bar--> | ||
| Line 1,632: | Line 1,407: | ||
<nav> | <nav> | ||
<a href="#intro" class="active">Introduction</a> | <a href="#intro" class="active">Introduction</a> | ||
| − | <a href="# | + | <a href="#outreach">Outreach</a> |
| − | <a href="# | + | <a class="sub-level" href="#university">University outreach</a> |
| + | <a class="sub-level" href="#public">Public outreach</a> | ||
| + | <a href="#safety">Safety</a> | ||
| + | <a href="#references">References</a> | ||
</nav> | </nav> | ||
</div> | </div> | ||
| Line 1,639: | Line 1,417: | ||
<div class="wrap-content"> | <div class="wrap-content"> | ||
| + | |||
<div class="dashed_line_left_first"> | <div class="dashed_line_left_first"> | ||
<div class="target" id="intro"> | <div class="target" id="intro"> | ||
<h4 class="subtitle">Introduction</h4> | <h4 class="subtitle">Introduction</h4> | ||
| − | <p class="text"> | + | <p class="text"> |
| − | + | The iGEM competition is a <b>lot more than just wet lab and modelling</b>. With the rapid development in synthetic biology, the need for creating awareness on how it could potentially affect the society and environment is great. Human practices entails considering all the different aspects that is influenced by the new technology. These can include <b>ethical, social, legal, and economical issues</b> as well as concerns regarding <b>biosafety</b>. | |
| − | + | </p> | |
| − | + | <p class="text"> | |
| − | + | In our project, we aimed to <b>spread information</b> about the applications of synthetic biology and its potential in helping solve some of the problems in the world. We did this by having lectures both at our own university for students and at Lund’s University for the public. We wanted to reach out and get people interested in the field and <b>inspire to think outside the box</b> by solving problems using applications no one thought imaginable, for example using baker's yeast for detection of lung cancer. | |
| − | + | </p> | |
| − | + | <p class="text"> | |
| − | + | To further reach out and integrate human practices in the project, we developed a <b>screening program</b> for lung cancer, which involved working with the different criterias for screening programs, including <b>biosafety</b>, carry out discussions with scientists and physicians within the field, designing and producing a <b>prototype </b>and creating and spreading a <b>survey</b> concerning the public’s view on a potential screening program for lung cancer. | |
| − | + | </p> | |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
</div> | </div> | ||
| − | </div> | + | </div> |
| − | + | ||
<div class="dashed_line_right"> | <div class="dashed_line_right"> | ||
| − | <div class="target" id=" | + | <div class="target" id="outreach"> |
| − | <h4 class="subtitle"> | + | <h4 class="subtitle">Outreach</h4> |
| − | <p class="text"> | + | <p class="text"> |
| − | + | An important part of every iGEM project is to <b>spread information about synthetic biology</b> and its applications to the public. It is also important to <b>reach out</b> to the public and tell them about your own project and answer the questions that they might have and <b>establish a dialogue</b>. To do this we did some outreach to the university and the public through different channels and in different ways. | |
| − | + | </p> | |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
</div> | </div> | ||
</div> | </div> | ||
| − | + | <div class="dashed_line_left"> | |
| − | <div class="target" id=" | + | <div class="target" id="university"> |
| − | + | <h2 class="h2style">University outreach</h2> | |
| − | <p class="text"> | + | <p class="text"> |
| − | + | We wanted to make our whole university aware of the cool project that we were working on and therefore decided to spread information about iGEM and our BREATHtaking biosensor. We did this in two ways; by having a <b>lunch lecture</b> and and also making a <b>mini series</b> about the project in cooperation with Chalmers University of Technology. | |
| − | + | </p> | |
| − | + | <p class="text"> | |
| − | + | The <b>lunch lecture</b> was about iGEM and our project and was conducted for Chalmers students, primarily biotechnology students. We answered questions and encouraged the students to get interested in synthetic biology, to support us and join the team next year. | |
| − | + | </p> | |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
</div> | </div> | ||
| + | |||
| + | <figure> | ||
| + | <img src="https://static.igem.org/mediawiki/2017/8/84/T--Chalmers-Gothenburg--Nollan-presentation-cut.jpg" alt="Chalmers presentation" style="height:500px; width:750px;"> | ||
| + | </figure> | ||
</div> | </div> | ||
| + | <div class="dashed_line_right"> | ||
| + | <p class="text"> | ||
| + | Even though the lunch lecture was great, the team was not content with only reaching out to biotechnology students. Therefore we reached out to <b>Chalmers Public Relations</b> section and they made a <b>mini series</b> in three parts which they distributed on their Facebook page. This way, we reached a broader crowd, both within and outside the university. In the two first episodes we explain our project, our achievements and <b>plan for the Jamboree in Boston</b>. The last episode will be released after Boston, where the viewers will see how great the Jamboree in Boston was. | ||
| + | </p> | ||
| + | </div> | ||
| + | |||
| + | <div class="target" id="public"> | ||
| + | <div class="dashed_line_left"> | ||
| + | <h2 class="h2style">Public outreach</h2> | ||
| + | <h2> | ||
| + | Lecture about synthetic biology with team iGEM Lund | ||
| + | </h2> | ||
| + | <p class="text"> | ||
| + | We <b>collaborated</b> with team <b>iGEM Lund</b> and held a lecture about synthetic biology in Lund at Lunds University’s 350 year anniversary. The lecture was open for the public and the information was kept at a popular scientific level. The lecture started with the <b>history of traditional genetic engineering</b> and continued with the description of <b>synthetic biology</b>. When the audience understood the concept of synthetic biology, each iGEM team presented their own project and how they used synthetic biology. | ||
| + | </p> | ||
| + | <figure> | ||
| + | <img src="https://static.igem.org/mediawiki/2017/8/85/T--Chalmers-Gothenburg--Lund.JPG" alt="Lund presentation" style="height:500px; width:750px;"> | ||
| + | </figure> | ||
| + | </div> | ||
| + | |||
| + | <div class="dashed_line_right"> | ||
| + | <p class="text"> | ||
| + | The lecture continued with <b>future applications</b> of synthetic biology and the <b>ethical aspects</b> were discussed. Research and responsibility goes hand in hand and the main message of this part was that it is important to think and discuss ethical dilemmas and questions before conducting any experiment. Different views on different subjects were presented in a natural way to let the audience create their own opinion. The lecture ended with a talk about <b>scientific communication</b>; how the communication work between researchers and the public today and why it is important to establish such a conversation. | ||
| + | </p> | ||
| + | <p class="text"> | ||
| + | After the lecture, the audience had the possibility to <b>talk with the speakers</b> and either ask questions or discuss specific subjects. There were questions about the project and some discussion about ethics, showing that the audience got interested and started to form their own opinions. | ||
| + | </p> | ||
| + | </div> | ||
| + | |||
| + | <div class="dashed_line_left"> | ||
| + | <h2> | ||
| + | Lung cancer survey | ||
| + | </h2> | ||
| + | <p class="text"> | ||
| + | To further reach out to the public and to get their help when designing a screening program, we created a <b>survey</b> about lung cancer screening program. We wanted to see what the public thought about having regular examinations for lung cancer, similar to how we screen for breast cancer in Sweden. We also investigated if the public thought that the tax money should finance or subsidized these screenings. This survey was open for everyone to answer and spread via different communication channels. A few more results from the survey is presented in <a href="https://2017.igem.org/Team:Chalmers-Gothenburg/HP/Gold_Integrated">Integrated human practices, screening program</a>. | ||
| + | </p> | ||
| + | </div> | ||
| + | |||
| + | <div class="dashed_line_right"> | ||
| + | <p class="text"> | ||
| + | We <b>collaborated</b> with <b>iGEM Bilkent-UNAMBG</b> and let them distribute the survey in their country to see if the results would differ between countries. The participation was good, with 605 and 268 participants in Sweden and Turkey respectively. | ||
| + | </p> | ||
| + | <p class="text"> | ||
| + | When asking the question: “If you would have been called for a free regular medical checkup (screening) for lung cancer every year, would you go?” both countries showed identical results, see Figure 1. The <b>majority</b> of the participants (89 %) in the survey <b>would go</b> to the medical check-up, showing a positive attitude for the screening program. | ||
| + | </p> | ||
| + | |||
| + | <figure> | ||
| + | <img src="https://static.igem.org/mediawiki/2017/e/ed/T--Chalmers-Gothenburg--survey1.png" alt="Survey answers" style="height:283px; width:486px;"> | ||
| + | <figcaption><b>Figure 1.</b> Results for the question: <i>“If you would have been called for a free regular medical checkup (screening) for lung cancer every year, would you go?”</i></figcaption> | ||
| + | </figure> | ||
| + | </div> | ||
| + | |||
| + | |||
| + | <div class="dashed_line_left"> | ||
| + | <p class="text"> | ||
| + | When asked the following question: “Do you think such a screening program should be totally financed or subsidized by the government?” the result showed that <b>most of the participants</b> think a lung cancer screening program should be either <b>funded or subsidized by the government</b>, seeFigure 2. The large difference between the countries is that most participants for Sweden think a subsidization would be the best while the majority from Turkey believe that the whole screening program should be financed by the government. Overall, there seems to be a positive attitude about setting up a lung screening program in both countries. | ||
| + | </p> | ||
| + | |||
| + | <figure> | ||
| + | <img src="https://static.igem.org/mediawiki/2017/7/76/T--Chalmers-Gothenburg--survey2.png" alt="Survey answers" style="height:283px; width:486px;"> | ||
| + | <figcaption><b>Figure 2.</b> Results for the question: <i>“Do you think such a screening program should be totally financed or subsidized by the government?”</i></figcaption> | ||
| + | </figure> | ||
| + | </div> | ||
| + | |||
| + | <div class="target" id="safety"> | ||
| + | <div class="dashed_line_right"> | ||
| + | <h4 class="subtitle">Safety</h4> | ||
| + | <p class="text"> | ||
| + | A vital part of working with the project and creating a screening program was to <b>take the safety into consideration</b>. It is important to ensure that <b>neither patients, hospital nor lab workers would be exposed to any risks.</b> | ||
| + | </p> | ||
| + | <p class="text"> | ||
| + | The first step was to make sure that neither patients or physicians would be in contact with the genetically modified yeast created in this project. If the risk of exposure is removed, it will also simplify the regulation issues. The exposure will be reduced using a prototype with a specific filter that will bind the VOCs when breathed on by the patient. This design allows the patient to breath into the prototype several times to increase the amount of VOCs trapped in the filter. The filter can then be sent to laboratory facilities where the VOCs are dissolved and exposed to the yeast to enable detection. See a more detailed description of the method in <a href="https://2017.igem.org/Team:Chalmers-Gothenburg/HP/Gold_Integrated">Integrated human practices, the prototype</a>. With this design, the need to bring genetically modified yeast into a hospital environment is made redundant. In Sweden a specific approval is needed to be able to work with genetically modified organisms and it would be the most efficient to use laboratory facilities that already have this approval [1]. Another benefit with this design is that there is absolutely <b>no risk for patients to inhale</b> the genetically modified yeast. | ||
| + | </p> | ||
| + | </div> | ||
| + | |||
| + | <div class="dashed_line_left"> | ||
| + | <p class="text"> | ||
| + | The second step was to ensure that the yeast used as a biosensor is in <b>no way dangerous to the environment</b> or to </b>the people working with it in the laboratory facilities</b>. Risk assessment of the procedures connected to the biosensor show the normal risk associated with working in a laboratory environment. With the </b>right knowledge, correct safety clothing</b> and <b>precautions</b>, the laboratory personnel should <b>not be exposed to any harm</b>. For more information regarding the safety, see <a href="https://2017.igem.org/Team:Chalmers-Gothenburg/Safety">Notebook, safety</a>. | ||
| + | </p> | ||
| + | <p class="text"> | ||
| + | When working with genetically modified organisms it is important to consider the ethical aspects and acknowledge possible hazards for the environment. In this case, <b>the yeast should be limited to the laboratory environment and not be spread or get in contact with nature. </b> | ||
| + | </p> | ||
| + | </div> | ||
| + | </div> | ||
| + | |||
| + | <div class="dashed_line_right_last"> | ||
| + | <div class="target" id="references"> | ||
| + | <h4 class="subtitle">References</h4> | ||
| + | <div class="reference_list"> | ||
| + | <ul> | ||
| + | <li>[1]   Innesluten användning av genetiskt modifierade mikroorganismer (AFS 2011:2) [Internet]. Stockholm: Anna Middelman [cited 170920]. Available from: https://www.av.se/globalassets/filer/publikationer/foreskrifter/innesluten-anvandning-av-genetiskt-modifierade-mikroorganismer-afs2011-2.pdf. | ||
| + | </li> | ||
| + | </ul> | ||
| + | </div> | ||
| + | </div> | ||
| + | </div> | ||
| + | |||
| + | </div> | ||
</div> <!--------------------------- HP_hp STOP --------------------------------> | </div> <!--------------------------- HP_hp STOP --------------------------------> | ||
| Line 1,712: | Line 1,570: | ||
<div id="logorow"> | <div id="logorow"> | ||
| + | |||
<div class="footerlogo"> | <div class="footerlogo"> | ||
| − | <a href=" | + | <a href="https://www.agilent.com/home" target="_blank"> |
| − | <img src=" | + | <img src="https://static.igem.org/mediawiki/2017/f/fb/T--Chalmers-Gothenburg--Agilent_gray.png" alt="Agilent Technologies" class="footerimg on"> |
| − | <img src=" | + | <img src="https://static.igem.org/mediawiki/2017/1/1e/T--Chalmers-Gothenburg--Agilent.png" alt="Agilent Technologies" class="footerimg off"> |
</a> | </a> | ||
</div> | </div> | ||
<div class="footerlogo"> | <div class="footerlogo"> | ||
| − | <a href="https://www. | + | <a href="https://www.atum.bio/" target="_blank"> |
| − | <img src=" | + | <img src="https://static.igem.org/mediawiki/2017/a/ae/T--Chalmers-Gothenburg--ATUM_gray.png" alt="ATUM" class="footerimg on"> |
| − | <img src=" | + | <img src="https://static.igem.org/mediawiki/2017/7/71/T--Chalmers-Gothenburg--ATUM.png" alt="ATUM" class="footerimg off"> |
</a> | </a> | ||
</div> | </div> | ||
<div class="footerlogo"> | <div class="footerlogo"> | ||
| − | <a href=" | + | <a href="http://www.chalmers.se/en/Pages/default.aspx" target="_blank"> |
| − | <img src=" | + | <img src="https://static.igem.org/mediawiki/2017/9/9f/T--Chalmers-Gothenburg--Chalmers_logo_gray.png" alt="Chalmers" class="footerimg on"> |
| − | <img src=" | + | <img src="https://static.igem.org/mediawiki/2017/9/9f/T--Chalmers-Gothenburg--Chalmers_logo.png" alt="Chalmers" class="footerimg off"> |
</a> | </a> | ||
</div> | </div> | ||
<div class="footerlogo"> | <div class="footerlogo"> | ||
| − | <a href="http://www.eurofins.com/"> | + | <a href="http://www.eurofins.com/" target="_blank"> |
| − | <img src=" | + | <img src="https://static.igem.org/mediawiki/2017/f/f8/T--Chalmers-Gothenburg--eurofins_gray.png" alt="Eurofins" class="footerimg on"> |
| − | <img src=" | + | <img src="https://static.igem.org/mediawiki/2017/e/e4/T--Chalmers-Gothenburg--eurofins.png" alt="Eurofins" class="footerimg off"> |
</a> | </a> | ||
</div> | </div> | ||
| − | + | ||
<div class="footerlogo"> | <div class="footerlogo"> | ||
| − | <a href=" | + | <a href="https://www.gatc-biotech.com/en/index.html" target=”_blank”> |
| − | <img src=" | + | <img src="https://static.igem.org/mediawiki/2017/c/c2/T--Chalmers-Gothenburg--gatc_gray.png" alt="GATC Biotech" class="footerimg on"> |
| − | <img src=" | + | <img src="https://static.igem.org/mediawiki/2017/c/c0/T--Chalmers-Gothenburg--gatc.png" alt="GATC Biotech" class="footerimg off"> |
</a> | </a> | ||
</div> | </div> | ||
<div class="footerlogo"> | <div class="footerlogo"> | ||
| − | <a href="http://www. | + | <a href="http://www.genscript.com/" target="_blank"> |
| − | <img src=" | + | <img src="https://static.igem.org/mediawiki/2017/c/ce/T--Chalmers-Gothenburg--Genscript_gray.png" alt="Genscript" class="footerimg on"> |
| − | <img src=" | + | <img src="https://static.igem.org/mediawiki/2017/2/29/T--Chalmers-Gothenburg--Genscript.png" alt="Genscript" class="footerimg off"> |
| + | </a> | ||
| + | </div> | ||
| + | |||
| + | <div class="footerlogo"> | ||
| + | <a href="https://www.idtdna.com/" target="_blank"> | ||
| + | <img src="https://static.igem.org/mediawiki/2017/a/a3/T--Chalmers-Gothenburg--IDT_gray.png" alt="IDT" class="footerimg on"> | ||
| + | <img src="https://static.igem.org/mediawiki/2017/f/fd/T--Chalmers-Gothenburg--IDT.png" alt="IDT" class="footerimg off"> | ||
</a> | </a> | ||
</div> | </div> | ||
<div class="footerlogo"> | <div class="footerlogo"> | ||
| − | <a href=" | + | <a href="http://www.chalmers.se/en/areas-of-advance/lifescience/Pages/default.aspx" target="_blank"> |
| − | <img src=" | + | <img src="https://static.igem.org/mediawiki/2017/6/6e/T--Chalmers-Gothenburg--Life_science_gray.png" alt="ATUM" class="footerimg on"> |
| − | <img src=" | + | <img src="https://static.igem.org/mediawiki/2017/a/a3/T--Chalmers-Gothenburg--Life_science.png" alt="ATUM" class="footerimg off"> |
</a> | </a> | ||
</div> | </div> | ||
| + | <div class="footerlogo"> | ||
| + | <a href="https://www.neb.com/" target="_blank"> | ||
| + | <img src="https://static.igem.org/mediawiki/2017/2/29/T--Chalmers-Gothenburg--neb_gray.png" alt="NEB" class="footerimg on"> | ||
| + | <img src="https://static.igem.org/mediawiki/2017/e/e6/T--Chalmers-Gothenburg--neb.png" alt="NEB" class="footerimg off"> | ||
| + | </a> | ||
| + | </div> | ||
<div class="footerlogo"> | <div class="footerlogo"> | ||
| − | <a href="http://www. | + | <a href="http://www.snapgene.com/" target="_blank"> |
| − | <img src=" | + | <img src="https://static.igem.org/mediawiki/2017/1/1a/T--Chalmers-Gothenburg--SnapGene_gray.png" alt="SnapGene" class="footerimg on"> |
| − | <img src=" | + | <img src="https://static.igem.org/mediawiki/2017/9/95/T--Chalmers-Gothenburg--SnapGene.png" alt="SnapGene" class="footerimg off"> |
</a> | </a> | ||
</div> | </div> | ||
| − | + | ||
| − | + | <div class="footerlogo"> | |
| − | + | <a href="http://www.sysbio.se/" target="_blank"> | |
| − | <a href="http://www. | + | <img src="https://static.igem.org/mediawiki/2017/7/7d/T--Chalmers-Gothenburg--sysbio_gray.png" alt="Sysbio" class="footerimg on"> |
| − | <img src=" | + | <img src="https://static.igem.org/mediawiki/2017/8/89/T--Chalmers-Gothenburg--sysbio.png" alt="Sysbio" class="footerimg off"> |
| − | <img src=" | + | |
</a> | </a> | ||
</div> | </div> | ||
| − | + | ||
| + | |||
<div id="footer-contact-row"> | <div id="footer-contact-row"> | ||
<hr> | <hr> | ||
| − | <a href="https://www.facebook.com/chalmersigem/?fref=ts">facebook</a> | + | <a href="https://www.facebook.com/chalmersigem/?fref=ts" target="_blank">facebook</a> |
| − | <a href="https://twitter.com/igemchalmers">twitter</a> | + | <a href="https://twitter.com/igemchalmers" target="_blank">twitter</a> |
<a href="mailto:igemgothenburg@gmail.com">e-mail</a> | <a href="mailto:igemgothenburg@gmail.com">e-mail</a> | ||
| − | <a href="https://www.instagram.com/chalmersigem/">instagram</a> | + | <a href="https://www.instagram.com/chalmersigem/" target="_blank">instagram</a> |
</div> | </div> | ||
| − | + | </footer> <!--------------------------------- footer_170726.html STOP ----------------------------------> </body> | |
| − | </footer> <!--------------------------------- footer_170726.html STOP ----------------------------------> | + | |
| − | + | ||
Latest revision as of 16:30, 30 October 2017
Introduction
The iGEM competition is a lot more than just wet lab and modelling. With the rapid development in synthetic biology, the need for creating awareness on how it could potentially affect the society and environment is great. Human practices entails considering all the different aspects that is influenced by the new technology. These can include ethical, social, legal, and economical issues as well as concerns regarding biosafety.
In our project, we aimed to spread information about the applications of synthetic biology and its potential in helping solve some of the problems in the world. We did this by having lectures both at our own university for students and at Lund’s University for the public. We wanted to reach out and get people interested in the field and inspire to think outside the box by solving problems using applications no one thought imaginable, for example using baker's yeast for detection of lung cancer.
To further reach out and integrate human practices in the project, we developed a screening program for lung cancer, which involved working with the different criterias for screening programs, including biosafety, carry out discussions with scientists and physicians within the field, designing and producing a prototype and creating and spreading a survey concerning the public’s view on a potential screening program for lung cancer.
Outreach
An important part of every iGEM project is to spread information about synthetic biology and its applications to the public. It is also important to reach out to the public and tell them about your own project and answer the questions that they might have and establish a dialogue. To do this we did some outreach to the university and the public through different channels and in different ways.
University outreach
We wanted to make our whole university aware of the cool project that we were working on and therefore decided to spread information about iGEM and our BREATHtaking biosensor. We did this in two ways; by having a lunch lecture and and also making a mini series about the project in cooperation with Chalmers University of Technology.
The lunch lecture was about iGEM and our project and was conducted for Chalmers students, primarily biotechnology students. We answered questions and encouraged the students to get interested in synthetic biology, to support us and join the team next year.
Even though the lunch lecture was great, the team was not content with only reaching out to biotechnology students. Therefore we reached out to Chalmers Public Relations section and they made a mini series in three parts which they distributed on their Facebook page. This way, we reached a broader crowd, both within and outside the university. In the two first episodes we explain our project, our achievements and plan for the Jamboree in Boston. The last episode will be released after Boston, where the viewers will see how great the Jamboree in Boston was.
Public outreach
Lecture about synthetic biology with team iGEM Lund
We collaborated with team iGEM Lund and held a lecture about synthetic biology in Lund at Lunds University’s 350 year anniversary. The lecture was open for the public and the information was kept at a popular scientific level. The lecture started with the history of traditional genetic engineering and continued with the description of synthetic biology. When the audience understood the concept of synthetic biology, each iGEM team presented their own project and how they used synthetic biology.
The lecture continued with future applications of synthetic biology and the ethical aspects were discussed. Research and responsibility goes hand in hand and the main message of this part was that it is important to think and discuss ethical dilemmas and questions before conducting any experiment. Different views on different subjects were presented in a natural way to let the audience create their own opinion. The lecture ended with a talk about scientific communication; how the communication work between researchers and the public today and why it is important to establish such a conversation.
After the lecture, the audience had the possibility to talk with the speakers and either ask questions or discuss specific subjects. There were questions about the project and some discussion about ethics, showing that the audience got interested and started to form their own opinions.
Lung cancer survey
To further reach out to the public and to get their help when designing a screening program, we created a survey about lung cancer screening program. We wanted to see what the public thought about having regular examinations for lung cancer, similar to how we screen for breast cancer in Sweden. We also investigated if the public thought that the tax money should finance or subsidized these screenings. This survey was open for everyone to answer and spread via different communication channels. A few more results from the survey is presented in Integrated human practices, screening program.
We collaborated with iGEM Bilkent-UNAMBG and let them distribute the survey in their country to see if the results would differ between countries. The participation was good, with 605 and 268 participants in Sweden and Turkey respectively.
When asking the question: “If you would have been called for a free regular medical checkup (screening) for lung cancer every year, would you go?” both countries showed identical results, see Figure 1. The majority of the participants (89 %) in the survey would go to the medical check-up, showing a positive attitude for the screening program.
When asked the following question: “Do you think such a screening program should be totally financed or subsidized by the government?” the result showed that most of the participants think a lung cancer screening program should be either funded or subsidized by the government, seeFigure 2. The large difference between the countries is that most participants for Sweden think a subsidization would be the best while the majority from Turkey believe that the whole screening program should be financed by the government. Overall, there seems to be a positive attitude about setting up a lung screening program in both countries.
Safety
A vital part of working with the project and creating a screening program was to take the safety into consideration. It is important to ensure that neither patients, hospital nor lab workers would be exposed to any risks.
The first step was to make sure that neither patients or physicians would be in contact with the genetically modified yeast created in this project. If the risk of exposure is removed, it will also simplify the regulation issues. The exposure will be reduced using a prototype with a specific filter that will bind the VOCs when breathed on by the patient. This design allows the patient to breath into the prototype several times to increase the amount of VOCs trapped in the filter. The filter can then be sent to laboratory facilities where the VOCs are dissolved and exposed to the yeast to enable detection. See a more detailed description of the method in Integrated human practices, the prototype. With this design, the need to bring genetically modified yeast into a hospital environment is made redundant. In Sweden a specific approval is needed to be able to work with genetically modified organisms and it would be the most efficient to use laboratory facilities that already have this approval [1]. Another benefit with this design is that there is absolutely no risk for patients to inhale the genetically modified yeast.
The second step was to ensure that the yeast used as a biosensor is in no way dangerous to the environment or to the people working with it in the laboratory facilities. Risk assessment of the procedures connected to the biosensor show the normal risk associated with working in a laboratory environment. With the right knowledge, correct safety clothing and precautions, the laboratory personnel should not be exposed to any harm. For more information regarding the safety, see Notebook, safety.
When working with genetically modified organisms it is important to consider the ethical aspects and acknowledge possible hazards for the environment. In this case, the yeast should be limited to the laboratory environment and not be spread or get in contact with nature.
References
- [1] Innesluten användning av genetiskt modifierade mikroorganismer (AFS 2011:2) [Internet]. Stockholm: Anna Middelman [cited 170920]. Available from: https://www.av.se/globalassets/filer/publikationer/foreskrifter/innesluten-anvandning-av-genetiskt-modifierade-mikroorganismer-afs2011-2.pdf.
